ANV-419 is under clinical development by Anaveon and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData, Phase II drugs for Relapsed Multiple Myeloma have a 31% phase ...
FP008 is a proprietary and patented drug candidate using Fapon Biopharma's cutting-edge antibody technology. As a first-in-class biologic, FP008 uniquely combines an engineered IL-10 monomer (IL-10M) ...